News - Pharmaceutical
Teva Pharmaceutical Industries Ltd reports launch of USD3.0bn syndicated ...
19 December 2012
According to the company's EVP and CFO, Eyal Desheh, by signing this new revolving credit facility, with its increased size and extended term, the company took another step towards its new strategy and secured ample liquidity to support its future growth.
Click on the link to read the full article at MENAFN.COM (This link will open in a new window)ONO PHARMACEUTICAL CO., LTD. : Phase III Trial of L-BLP25 (Stimuvax
19 December 2012
Merck Serono, a division of Merck, Darmstadt, Germany, announced today that the Phase III START trial of its investigational product L-BLP25 (formerly referred to as Stimuvax
Click on the link to read the full article at 4-traders (This link will open in a new window)Teva Pharmaceutical Gets $3 Billion Credit Line to Replace Debt
18 December 2012
Teva Pharmaceutical Industries Ltd. (TEVA), the world's largest maker of generic drugs, got a $3 billion revolving credit line to replace a smaller loan. Citigroup Inc. and HSBC Bank Plc arranged the five-year revolver replacing a $2.5 billion ...
Click on the link to read the full article at Bloomberg (This link will open in a new window)"Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2012 ...
18 December 2012
Boston, MA -- (SBWIRE) -- 12/18/2012 -- Global Market Direct's pharmaceuticals report, "Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2012" provides data on the Lee's Pharmaceutical Holdings Limited's research and development focus ...
Click on the link to read the full article at SBWire (press release) (This link will open in a new window)UK pharmaceutical stocks 'at risk of becoming value traps'
18 December 2012
Mr Lang, who with colleague William Pattisson runs the
Click on the link to read the full article at FT Adviser (This link will open in a new window)Strengthening of Pharmaceutical Network Regulation Defended
18 December 2012
Luanda ? The Inspector-General of Health, Miguel dos Santos de Oliveira, Monday in Luanda defended the need of strengthening the regulation, supervision and monitoring mechanisms of all pharmaceutical system in order to ensure quality, efficiency and ...
Click on the link to read the full article at AllAfrica.com (This link will open in a new window)GIS, FLDM set up single-cell genomics research center in Singapore
17 December 2012
The Genome Institute of Singapore (GIS) and Fluidigm Corporation (FLDM) have established GIS-Fluidigm Single-Cell 'Omics Center (SCOC) to speed up the understanding of how individual cells work and how diagnosis and treatment might be improved ...
Click on the link to read the full article at Pharmaceutical Business Review (This link will open in a new window)U.S. Corporate Credit Swaps Rise; Teva Pharmaceutical Plans Bond
14 December 2012
Teva Pharmaceutical Industries Ltd. (TEVA), the world's largest maker of generic drugs, is offering $2 billion of dollar- denominated bonds in its first U.S. sale this year. Proceeds will be used for general corporate purposes, the Petach Tikva, Israel ...
Click on the link to read the full article at Bloomberg (This link will open in a new window)Iran, India to boost pharmaceutical exports
14 December 2012
The Pharmaceutical Export Promotion Council of India is organizing a trip to Tehran in the next few days in order to boost pharmaceutical exports between the two countries. The move comes as the Indian rupee has been made the official currency for ...
Click on the link to read the full article at Press TV (This link will open in a new window)CHUGAI PHARMACEUTICAL CO., LTD. : Notice concerning adoption of ...
14 December 2012
Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, Chugai)] has decided to voluntary adopt International Financial Reporting Standards (IFRS) for use in the consolidated financial statements and ...
Click on the link to read the full article at 4-traders (This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
